Kilitch Drugs (India) Limited Stock

Equities

524500

INE729D01010

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:50 2024-04-26 EDT 5-day change 1st Jan Change
358.6 INR +2.15% Intraday chart for Kilitch Drugs (India) Limited +3.43% -3.54%

Financials

Sales 2022 1.14B 13.7M 18.73M Sales 2023 1.4B 16.74M 22.89M Capitalization 2.17B 26.08M 35.66M
Net income 2022 73M 876K 1.2M Net income 2023 104M 1.25M 1.71M EV / Sales 2022 1.96 x
Net cash position 2022 369M 4.42M 6.04M Net cash position 2023 370M 4.44M 6.06M EV / Sales 2023 1.29 x
P/E ratio 2022
35.5 x
P/E ratio 2023
20.8 x
Employees 153
Yield 2022 *
-
Yield 2023
-
Free-Float 23.7%
More Fundamentals * Assessed data
Dynamic Chart
Kilitch Drugs (India) Unit Bags Supply Contract from Ethiopia MT
Kilitch Drugs Limited Wins Tender Issued by the Federal Democratic Republic of Ethiopia Pharmaceutical Supply Service for Supply of Pharmaceuticals CI
Kilitch Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Kilitch Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Kilitch Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Kilitch Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Kilitch Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Kilitch Drugs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Kilitch Drugs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Kilitch Drugs Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Kilitch Drugs Limited Announces Management Changes CI
Kilitch Drugs Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Kilitch Drugs Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Bhavin Mehta completed the acquisition of 7.13% of stake in Kilitch Drugs Limited from Mukund Mehta. CI
Kilitch Drugs Limited Announces Resignation of Princy Asati as Company Secretary & Compliance Officer CI
More news
1 day+2.15%
1 week+3.43%
Current month-8.02%
1 month-8.02%
3 months-14.41%
6 months+41.18%
Current year-3.54%
More quotes
1 week
340.80
Extreme 340.8
367.70
1 month
336.20
Extreme 336.2
393.90
Current year
321.50
Extreme 321.5
469.85
1 year
157.00
Extreme 157
469.85
3 years
100.60
Extreme 100.6
469.85
5 years
63.00
Extreme 63
469.85
10 years
19.80
Extreme 19.8
469.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 92-05-11
Director of Finance/CFO 40 21-02-28
Compliance Officer - 22-05-04
Members of the board TitleAgeSince
Chief Executive Officer 70 92-05-11
Director/Board Member 48 07-09-28
Director/Board Member 58 15-03-31
More insiders
Date Price Change Volume
24-04-26 358.6 +2.15% 3,022
24-04-25 351 +0.41% 702
24-04-24 349.6 +0.16% 481
24-04-23 349 -1.59% 826
24-04-22 354.7 +2.31% 1,157

Delayed Quote Bombay S.E., April 26, 2024 at 06:00 am

More quotes
Kilitch Drugs (India) Limited is an India-based pharmaceutical manufacturing company. The Company is engaged in developing, manufacturing and marketing a range of pharmaceutical formulations. The Company’s products include Parenteral and Nasal Products, Oral, Effervescent, Nutritional Products, Medical Devices, and Cosmetics and Herbal Products. Its Parenteral and Nasal Products has a range of products that help in gastroenterology, anti-inflammatory, anti-malaria, diagnostic, uterine stimulants, veterinary and other areas in the form of ampoules and vials. Its range of oral formulations includes tablets, capsules, dry syrups and oral powders. It provides a range of cosmetics ranging from oil, lotion, liquid to cream and paste in the skin care, personal care and hair care categories. Its herbal products are useful for sore throat, prostate problems, and can be used as supplements for diabetes, obesity, libido and others. Its medical devices offer a C-Seal brand.
More about the company
  1. Stock Market
  2. Equities
  3. 524500 Stock